Seoul Court Overturns Health Ministry's 14-Percent Price Cut On Novartis' Glivec
This article was originally published in The Pink Sheet Daily
The threatened price cut is suspended until the court battle is played out between Novartis and the ministry, the Administrative Court ruled.
You may also be interested in...
Roche Hits A Wall With Its Tarceva Patent Claims In India; Novartis Moves Supreme Court For Glivec Rights
MUMBAI - For the two Swiss drug giants Novartis and Roche, there was much action at India's Supreme Court Aug. 28 as they separately continued the fight to safeguard patents on their life-saving oncology drugs steadfastly challenged by health activists and generic drug manufacturers alike in India
Facing Calls For Compulsory Licensing, Roche To Provide Fuzeon In Korea Under Compassionate Access Program
SEOUL - Nearly five years after refusing to supply its antiretroviral Fuzeon (enfuvirtide) to HIV/AIDS patients in South Korea due to pricing issues, Roche Korea says it will now provide the medication through its compassionate access program
SEOUL - South Korea's Ministry for Health, Welfare and Family Affairs is in pursuit of what it calls a "refunding system" under which multinational companies could sell their products at prices they want under the coverage of the local National Health Insurance System